Events

RSC-BMCS/SCI Targeting Protein Degradation 4

Event
RSC-BMCS/SCI Targeting Protein Degradation 4

Dates
15 October – 16 October 2024

Place
Cranfield University, UK

Important links
Twitter hashtag – #ProtDeg24
Please click here for main conference website

Synopsis
One of the most exciting new therapeutic modalities to emerge in the 21st century has been Targeted Protein Degradation (TPD). In 2021, the Targeted Protein Degradation Market size was valued at USD 400.5 million and is poised to grow from USD 507.0 million in 2022 to USD 3,300.0 million by 2030 and so has attracted interest from academia, non-profit organisations through to CROs and small and large pharma.

This multidisciplinary meeting aims to present the latest developments in the design, biology, chemistry and ADME in TPD within the general themes of PROTACS (including non-oncology targets), Molecular Glues and non-PROTAC degraders. We aim to highlight the newest in enabling technologies such as computational techniques, Direct to Biology, HT synthesis (click, photochemistry etc) and structural biology methods.

Who should attend
The meeting aims is targeted at academic and industrial scientists engaged in all aspects of research into the ubiquitin proteasome pathway and those interested in broadening their knowledge in this rapidly expanding field.

Call for Abstracts
Submissions for oral and/or poster presentations are welcomed around the conference general themes. Abstracts should be maximum 300 words indicating title, authors, institution and prefer­ence for presentation option (Oral presentation and/or Poster) and sent to conferences@soci.org with the subject line “Targeting Protein Degradation 2024 – abstract submission”. Presentation slots are inevitably limited and will be allocated to achieve a balanced programme. Prizes will be awarded for the best presentation and poster.

Deadline for oral presentations – Friday 31 May 2024 (decisions by end of June)
Deadline for poster presentations – Friday 30 August 2024

 

Programme

Tuesday 15th October 2024

09.45Registration
10.25Opening Remarks
10.30Plenary lecture: Gazing into the crystal ball - what have we learnt and where does TPD research need to go next?
Ian Churcher, Janus Drug Discovery
11.10Discovery of Novel Small Molecules Binders of Soluble Mutant HTT and Derivatization into PROTACs
Geoffrey Schwertz, UCB
11.35Discovery of BclxL protein degraders for overcoming cancer resistance
Jim Sheppeck, AZ
12.00Targeting cancer with panKRAS degraders
Vesna Vetma, Centre for Targeted Protein Degradation, Dundee
12.25Lunch
13.30Photocatalysis enabled One-Pot PROTAC Library Synthesis
Jacqueline Bitai, Boehringer Ingelheim
13.55Exploring the Pharmacokinetics of PROTACs: A Focus on Solubility and Metabolic Stability
Gabriele Cruciani, University of Perugia
14.20CRBN-midi: expanding the toolbox for structural and biophysical characterization of protein degraders
Alena Kroupova, Centre for Targeted Protein Degradation, Dundee
14.45Leveraging XChem Crystallographic Fragment Screening and Chemist-Assisted Robotics for Silent Hotspot Mapping and Rapid Fragment Expansion
Thomas Webb, Centre for Targeted Protein Degradation, Dundee
15.10Refreshments and Exhibition
15.40Making it stick – how can we convert inhibitors into molecular glue degraders?
Ben Bellenie, ICR Centre for Protein Degradation
16.20Identification, optimization and characterization of Cyclin K molecular glue degraders
Douglas Thomson, Proxygen
16.45Degradation of BRD9 by a novel targeted glue
Andrea Testa, Amphista Therapeutics
17.10Flash Poster Presentations
17.30Poster presentations and networking drinks (till 18.10)
19.00Conference Dinner

Wednesday 16th October 2024

09.00Registration and Exhibition
09.15Plenary lecture: Molecular mechanisms and rational design of protein degraders
Alessio Ciulli, Centre for Targeted Protein Degradation, Dundee
09.55Development and Application of Direct-to-Biology for High-Throughput PROTAC Synthesis and Testing
Rob Law, GSK
10.20RSC BMCS Hall of Fame Award and Lecture: A career doing STUFF
Mike Hann, GSK
11.00Refreshments and exhibition
11.30Enabling targeted protein degradation in bacteria
Ester Morreale, Crick Institute
11.55Development of the ULK1-Recruiting Chimeras (ULKRECs) to enable proximity-induced and ULK1-dependent degradation of “undruggable” targets
David Selwood, University College London
12.20Structural Insights into PROTAC Handle Development for the Cullin-2 Substrate Adaptor KLHDC2
Melissa Sweeney, University of Oxford
12.45Lunch
13.45Plenary lecture: Targeting chromatin regulatory proteins with therapeutic degraders
Danette Daniels, Foghorn Therapeutics
14.25TBC
14.55PROTAC-based approach to develop broad-spectrum antiviral agents triggering the proteolysis of the major viral protease
Alessia De Santis, University of Florence
15.20Activin Receptor-like Kinase 2 Degradation as a Novel Therapeutic Strategy Towards the Treatment of Diffuse Intrinsic Pontine Glioma
Daniel Webb, Charles River Laboratories
15.45Closing Remarks

Exhibitors/Sponsors
For further information and prices, please email conferences@soci.org.

Organising Committee
Sean Bew, UEA
Stuart Cameron, Concept life sciences
Nicola Chessum, Boehringer-Ingelheim
Katherine Jones, Charles River
Suzanne O’Connor, University of Dundee
Hannah Woodward, MSD